Study of a drug for enlarged prostate after sudden urinary blockage
Part of Kidney & urinary clinical trials.
This trial tests a drug called Teverelix DP to see if it can shrink an enlarged prostate and improve urinary function in men who recently had sudden urinary retention (couldn't pee). It may help prevent future episodes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 45 or older.
- You had your first sudden inability to urinate within the last 6 days, and you were able to pee again successfully after a catheter was removed.
- Your prostate is larger than 40 grams (about the size of a walnut or bigger).
- You have not had any prostate or urethra surgery or been diagnosed with prostate cancer.
- You do not have serious liver, kidney, or heart problems, and your PSA (a prostate cancer marker) is under 20 ng/mL.
- You are willing to use effective birth control or be abstinent during the study and for 3 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding tadalafil to tamsulosin helps men pass a catheter removal test after a first-time urinary blockage caused by an enlarged prostate. The goal is to find which treatment works best to avoid needing a catheter again.
This trial tests whether increasing your prostate medication (tamsulosin) or switching to a different medication (silodosin) helps you urinate normally again after a sudden blockage caused by an enlarged prostate. The goal is to help you avoid long-term catheter use.
This study compares two treatments for men with moderate to severe urinary symptoms from an enlarged prostate. It looks at whether taking an alpha blocker with a plant-based supplement (Serenoa repens/saw palmetto) works better or has fewer side effects than taking an alpha blocker with a medicine that calms bladder spasms (antimuscarinic).
This study tests a new injectable drug called Teverelix DP that blocks a natural hormone (GnRH) to lower testosterone and slow prostate cancer growth. It is for men with advanced prostate cancer that still responds to hormone therapy and who have not had GnRH-blocking treatments before.
This trial tests a new drug, DTT106, for men who have both erectile dysfunction and an enlarged prostate (BPH). It is for men already taking dutasteride and tamsulosin and aims to see if the new treatment improves erections better.
This trial tests new treatment strategies for benign prostatic hyperplasia (BPH, an enlarged prostate) using a special MRI scan and a medication called finasteride. It aims to find better ways to manage symptoms and identify markers that predict response.
Hear when a new Acute Urinary Retention trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.